Spots Global Cancer Trial Database for Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
Official Title: An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer
Study ID: NCT00328120
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Chiba, , Japan
Research Site, Fukuoka, , Japan
Research Site, Nagoyata, , Japan
Research Site, Osaka, , Japan
Research Site, Tokyo, , Japan
Contact Details
Name: Breast Cancer Established Brands Team Medical Science Director, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
